ESPR - Esperion Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5984.39M
Enterprise Value 3684.13M
Trailing P/E N/A
Forward P/E 1-10.01
PEG Ratio (5 yr expected) 1-0.47
Price/Sales (ttm)6.72
Price/Book (mrq)7.57
Enterprise Value/Revenue 34.67
Enterprise Value/EBITDA 6-8.63

Trading Information

Stock Price History

Beta (3Y Monthly) 1.15
52-Week Change 3-14.75%
S&P500 52-Week Change 32.99%
52 Week High 360.99
52 Week Low 333.13
50-Day Moving Average 337.07
200-Day Moving Average 343.80

Share Statistics

Avg Vol (3 month) 3446.61k
Avg Vol (10 day) 3371.45k
Shares Outstanding 527.17M
Float 22.48M
% Held by Insiders 15.03%
% Held by Institutions 1108.60%
Shares Short (Aug 15, 2019) 45.22M
Short Ratio (Aug 15, 2019) 411.25
Short % of Float (Aug 15, 2019) 425.58%
Short % of Shares Outstanding (Aug 15, 2019) 419.22%
Shares Short (prior month Jul 15, 2019) 45.09M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 26/1
Last Split Date 3Jun 11, 2013

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019

Profitability

Profit Margin -52.45%
Operating Margin (ttm)-54.36%

Management Effectiveness

Return on Assets (ttm)-19.14%
Return on Equity (ttm)-50.31%

Income Statement

Revenue (ttm)146.4M
Revenue Per Share (ttm)5.45
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -79.31M
Net Income Avi to Common (ttm)-76.79M
Diluted EPS (ttm)-2.86
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)301.23M
Total Cash Per Share (mrq)11.09
Total Debt (mrq)958k
Total Debt/Equity (mrq)0.74
Current Ratio (mrq)5.66
Book Value Per Share (mrq)4.78

Cash Flow Statement

Operating Cash Flow (ttm)-28.54M
Levered Free Cash Flow (ttm)-2.43M